![Salvatore Alesci](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Salvatore Alesci
Directeur Technique/Scientifique/R&D chez
Invea Therapeutics, Inc.
Profil
Salvatore Alesci currently works at Invea Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. Alesci also formerly worked at National Foundation for Celiac Awareness, as Chief Scientist & Strategy Officer from 2020 to 2023, InveniAI LLC, as Chief Scientific Officer in 2021, and Takeda Pharmaceutical Co., Ltd., as Vice President & Head-Scientific Affairs from 2015 to 2019.
Dr. Alesci received his doctorate degree from the University of Messina.
Postes actifs de Salvatore Alesci
| Sociétés | Poste | Début |
|---|---|---|
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Directeur Technique/Scientifique/R&D | 01/01/2022 |
Anciens postes connus de Salvatore Alesci
| Sociétés | Poste | Fin |
|---|---|---|
National Foundation for Celiac Awareness
 National Foundation for Celiac Awareness Miscellaneous Commercial ServicesCommercial Services Operates foundations for raising awareness of celiac disease and gluten sensitivity | Corporate Officer/Principal | 01/10/2023 |
Inveniai LLC
 Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Corporate Officer/Principal | 01/12/2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/09/2019 |
Formation de Salvatore Alesci
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
University of Messina
 University of Messina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Foundation for Celiac Awareness
National Foundation for Celiac Awareness Miscellaneous Commercial ServicesCommercial Services Operates foundations for raising awareness of celiac disease and gluten sensitivity | Commercial Services |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
Inveniai LLC
Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Technology Services |
